P/E ratio for Abiomed (ABMD)
P/E ratio as of May 2024 (TTM): 64.8
According to Abiomed's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 64.7993. At the end of 2021 the company had a P/E ratio of 123.
P/E ratio history for Abiomed from 2013 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 123 | 68.26% |
| 2020 | 72.9 | 131.9% |
| 2019 | 31.4 | -52.06% |
| 2018 | 65.5 | -28.32% |
| 2017 | 91.4 | -8.32% |
| 2016 | 99.7 | 235.78% |
| 2015 | 29.7 | -64.89% |
| 2014 | 84.6 | -36.74% |
| 2013 | 134 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Boston Scientific BSX | 90.3 | 39.42% | 🇺🇸 USA |
 Teleflex TFX | 24.0 | -63.03% | 🇺🇸 USA |
 AtriCure ATRC | -40.5 | -162.52% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.